Diversified US health care group American Home should see its profit/earnings multiple continue to rise; it is a "strong buy," according to analysts Barbara Ryan and Catherine Knickerbocker of Alex Brown & Sons, who expect the stock to trade at 16 times their preliminary 1991 earnings per share forecast of $5.65, or at 90-95.
They say that investors should come to recognize the acceleration in earnings growth and the improved quality of EPS. The quality of earnings has also improved substantially; and fuelling earnings now is sales growth from new drugs rather than a declining sharebase and tax rate, as in previous years, they observe.
The emphasis of the company's management is now on health care and improving profitability, the analysts say, noting that a total of 91% of AHP's earnings currently emanate from health care, compared with 74.5% in 1986. Commensurate with this shift, net margins have expanded to an estimated 19% this year from 15%, and the analysts say that they expect this to rise to 21% in 1993.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze